Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1

Status

Completed 45Recruiting 21Active not recruiting 14Unknown 13Terminated 13Not yet recruiting 3Withdrawn 2

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 3

Conditions

Pancreatic Neoplasms 8Carcinoma, Non-Small-Cell Lung 7Esophageal Squamous Cell Carcinoma 5Triple Negative Breast Neoplasms 3Neoplasms 3Head and Neck Neoplasms 3Breast Neoplasms 3Stomach Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Neoplasm Metastasis 2Lung Neoplasms 2Uterine Cervical Neoplasms 1Thymoma 1Thymic epithelial tumor 1Squamous NSCLC 1Small Cell Lung Carcinoma 1Salivary Gland Malignant Neoplasms 1Pathologic Complete Response 1Pancreatic cancer, adult 1Pancreatic Cancer Resectable 1Melanoma 1Mediastinal Neoplasms 1Locally Advanced Non-Small Cell Lung Cancer 1Gastric Adenocarcinoma 1Fallopian Tube Neoplasms 1Esophageal Squamous Carcinoma 1Carcinoma 1Brain Neoplasms 1Anophthalmia with pulmonary hypoplasia 1Advanced Triple Negative Breast Cancer 1

Interventions

Trastuzumab 16pertuzumab 14Capecitabine 14Docetaxel 12pyrotinib 11Cyclophosphamide 11Standard of Care 10Paclitaxel 10Letrozole 10trastuzumab deruxtecan 9Radiotherapy 9Carboplatin 9Fulvestrant 8Drug Therapy 8sacituzumab govitecan 7dalpiciclib 7exemestane 6eribulin 6Tamoxifen 6Epirubicin 6Anastrozole 6pembrolizumab 5palbociclib 5abemaciclib 5Neoadjuvant Therapy 5Aromatase Inhibitors 5camrelizumab 4Surveys and Questionnaires 4Sentinel Lymph Node Biopsy 4Doxorubicin 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Not yet recruiting × Breast Neoplasms × 130-nm albumin-bound paclitaxel × Clear all
NCT07527806 2026-04-17

Optimization of Dynamic Neoadjuvant Therapy Strategies for HER2-Positive Breast Cancer Based on HER2-PET/CT Molecular Imaging

Peking University Cancer Hospital & Institute

Phase 2 Not yet recruiting
156 enrolled
Breast

Breast Neoplasms

NCT07245797 2025-11-24

A Phase II, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of Neoadjuvant Therapy With Inavolisib Plus Pertuzumab and Trastuzumab as Subcutaneous (PH-FDC SC) and 3-week Cycle Nab-paclitaxel for PIK3CA-mutated, HER2+, eBC

Fudan University

Phase 2 Not yet recruiting
164 enrolled
Breast

Breast Neoplasms

NCT06140576 2023-11-20

The Efficacy and Safety of Lenvatinib Combined With Sindilimab and Nab-paclitaxel in the First-line Treatment for Recurrent and Metastatic Triple Negative Breast Cancer: a Phase Ib/IIa Clinical Trial.

Zhejiang Cancer Hospital

Phase 1/2 Not yet recruiting
58 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡